Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413618 | 0.86 | DRD1 (0.57) | DRD1ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL16962151 | 0.81 | KDM4E (0.35) | DRD1KDM4EPOLBMAPTALOX15 | |
| SCHEMBL3154992 | 0.81 | DRD1 (0.33) | DRD1KDM4EPOLBMAPT | |
| SCHEMBL12038129 | 0.81 | ALDH1A3 (0.53) | ALDH1A1KDM4EMAOAMAOBALDH1A3 | |
| SCHEMBL3163240 | 0.80 | ALOX15 (0.36) | DRD1ALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL21945477 | 0.79 | DRD1 (0.50) | DRD1ALDH1A1ALOX15GFERADAM17 | |
| SCHEMBL2497078 | 0.78 | DRD1 (0.49) | DRD1ALDH1A1MAPTALDH1A3NPC1 | |
| SCHEMBL25752940 | 0.75 | DRD1 (0.46) | DRD1ALDH1A1POLBMAPTALDH1A3 | |
| SCHEMBL30374532 | 0.75 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9A | |
| SCHEMBL235612 | 0.75 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
| WO-2021230325-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | 宇部興産株式会社 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | DRD1 109/4885ALDH1A1 208/4885KDM4E 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.